Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
The Effects of Empagliflozin in Heart Failure with Preserved Ejection Fraction
FY 2020-21
Summary
The treatment of heart failure with preserved ejection fraction (HFpEF) is perhaps the most pressing unmet need in clinical cardiology. Despite accounting for approximately half of all heart failure patients, there remains no reliably effective treatment for HFpEF. Empagliflozin (EMPA) is an emerging therapy with promise in treating HFpEF. While large scale clinical trials are on-going to establish high-level effects, a fine grained understanding of how EMPA interacts with HFpEF is yet to be brought forward. Some existing research suggests EMPA protects the heart through a beneficial shift in cardiac metabolism. This mechanism is of particular interest in HFpEF, which often presents with metabolic dysfunction that may be improved by EMPA. Thus, my work aims to uncover the magnitude and nature of EMPA's effects in an animal model of HFpEF, with a particular focus upon metabolic alterations. By examining improvements in HFpEF symptoms in live animals, while simultaneously interrogating the driving mechanisms, this research will connect specific effects of EMPA to specific causes. This work promises to optimize the use of EMPA clinically, while enhancing our foundational understanding of HFpEF itself.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
449768
Name
Troy Aaron
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
The Effects of Empagliflozin in Heart Failure with Preserved Ejection Fraction
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cardiology; Diabetes; Heart Failure; Hypertension; Medical Imaging; Metabolism
Abstract
The treatment of heart failure with preserved ejection fraction (HFpEF) is perhaps the most pressing unmet need in clinical cardiology. Despite accounting for approximately half of all heart failure patients, there remains no reliably effective treatment for HFpEF. Empagliflozin (EMPA) is an emerging therapy with promise in treating HFpEF. While large scale clinical trials are on-going to establish high-level effects, a fine grained understanding of how EMPA interacts with HFpEF is yet to be brought forward. Some existing research suggests EMPA protects the heart through a beneficial shift in cardiac metabolism. This mechanism is of particular interest in HFpEF, which often presents with metabolic dysfunction that may be improved by EMPA. Thus, my work aims to uncover the magnitude and nature of EMPA's effects in an animal model of HFpEF, with a particular focus upon metabolic alterations. By examining improvements in HFpEF symptoms in live animals, while simultaneously interrogating the driving mechanisms, this research will connect specific effects of EMPA to specific causes. This work promises to optimize the use of EMPA clinically, while enhancing our foundational understanding of HFpEF itself.
Competitiondate
202012
Approvedterm2
1 yr 0 mth
Pinamesdelim
Troy, Aaron
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~